163 related articles for article (PubMed ID: 23955812)
1. Functional polymorphisms of matrix metalloproteinase-9 and survival in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy.
Liu H; Huang PY; Tang LQ; Chen QY; Zhang Y; Zhang L; Guo L; Luo DH; Mo HY; Xiang YQ; Qiu F; Sun R; Chen MY; Hua YJ; Lv X; Wang L; Zhao C; Guo X; Cao KJ; Qian CN; Hong MH; Mai HQ
Med Oncol; 2013 Dec; 30(4):685. PubMed ID: 23955812
[TBL] [Abstract][Full Text] [Related]
2. Genetic variations in radiation and chemotherapy drug action pathways and survival in locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy.
Liu H; Qi B; Guo X; Tang LQ; Chen QY; Zhang L; Guo L; Luo DH; Huang PY; Mo HY; Xiang YQ; Qiu F; Sun R; Zhang Y; Chen MY; Hua YJ; Lv X; Wang L; Zhao C; Cao KJ; Qian CN; Hong MH; Mai HQ
PLoS One; 2013; 8(12):e82750. PubMed ID: 24340057
[TBL] [Abstract][Full Text] [Related]
3. Polymorphisms in the endothelin-1 and endothelin a receptor genes and survival in patients with locoregionally advanced nasopharyngeal carcinoma.
Wen YF; Qi B; Liu H; Mo HY; Chen QY; Li J; Huang PY; Ye YF; Zhang Y; Deng MQ; Guo X; Hong MH; Cao KJ; Mai HQ
Clin Cancer Res; 2011 Apr; 17(8):2451-8. PubMed ID: 21487064
[TBL] [Abstract][Full Text] [Related]
4. Development and validation of a gene expression-based signature to predict distant metastasis in locoregionally advanced nasopharyngeal carcinoma: a retrospective, multicentre, cohort study.
Tang XR; Li YQ; Liang SB; Jiang W; Liu F; Ge WX; Tang LL; Mao YP; He QM; Yang XJ; Zhang Y; Wen X; Zhang J; Wang YQ; Zhang PP; Sun Y; Yun JP; Zeng J; Li L; Liu LZ; Liu N; Ma J
Lancet Oncol; 2018 Mar; 19(3):382-393. PubMed ID: 29428165
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial.
Cao SM; Yang Q; Guo L; Mai HQ; Mo HY; Cao KJ; Qian CN; Zhao C; Xiang YQ; Zhang XP; Lin ZX; Li WX; Liu Q; Qiu F; Sun R; Chen QY; Huang PY; Luo DH; Hua YJ; Wu YS; Lv X; Wang L; Xia WX; Tang LQ; Ye YF; Chen MY; Guo X; Hong MH
Eur J Cancer; 2017 Apr; 75():14-23. PubMed ID: 28214653
[TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinase-1 (-1607) 1G/2G and -9 (-1562) C/T promoter polymorphisms: susceptibility and prognostic implications in nasopharyngeal carcinomas.
Nasr HB; Mestiri S; Chahed K; Bouaouina N; Gabbouj S; Jalbout M; Chouchane L
Clin Chim Acta; 2007 Sep; 384(1-2):57-63. PubMed ID: 17599818
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of excision repair cross- complementation group 1 expression in locoregionally advanced nasopharyngeal carcinoma receiving cisplatin-based concurrent chemoradiotherapy.
Wang D; Zhou J; Zheng J; Zhang J; Chen Y; Li W; Wang R
Cancer Biomark; 2018; 21(4):875-881. PubMed ID: 29439312
[TBL] [Abstract][Full Text] [Related]
8. Serum miRNAs, a potential prognosis marker of loco-regionally advanced nasopharyngeal carcinoma patients treated with CCRT.
Zhang Z; Huang J; Wang G; Jin F; Zheng J; Xiao H; Lei L; Luo J; Chen C
BMC Cancer; 2020 Mar; 20(1):183. PubMed ID: 32131777
[TBL] [Abstract][Full Text] [Related]
9. The comparison of prognostic value of tumour volumetric regression ratio and RECIST 1.1 criteria after induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma.
Zeng YY; Xiang ZZ; He T; Liu F; Shao BF; Yan RN; Ma JC; Wang XR; Liu L
Oral Oncol; 2020 Dec; 111():104924. PubMed ID: 32736209
[TBL] [Abstract][Full Text] [Related]
10. Increased expression of MMP9 is correlated with poor prognosis of nasopharyngeal carcinoma.
Liu Z; Li L; Yang Z; Luo W; Li X; Yang H; Yao K; Wu B; Fang W
BMC Cancer; 2010 Jun; 10():270. PubMed ID: 20534121
[TBL] [Abstract][Full Text] [Related]
11. Expression of EIF5A2 associates with poor survival of nasopharyngeal carcinoma patients treated with induction chemotherapy.
Huang PY; Zeng TT; Ban X; Li MQ; Zhang BZ; Zhu YH; Hua WF; Mai HQ; Zhang L; Guan XY; Li Y
BMC Cancer; 2016 Aug; 16(1):669. PubMed ID: 27549330
[TBL] [Abstract][Full Text] [Related]
12. Survival benefit of adding chemotherapy to intensity modulated radiation in patients with locoregionally advanced nasopharyngeal carcinoma.
Ji X; Xie C; Hu D; Fan X; Zhou Y; Zheng Y
PLoS One; 2013; 8(2):e56208. PubMed ID: 23441169
[TBL] [Abstract][Full Text] [Related]
13. Effect of induction chemotherapy with cisplatin, fluorouracil, with or without taxane on locoregionally advanced nasopharyngeal carcinoma: a retrospective, propensity score-matched analysis.
Liu GY; Lv X; Wu YS; Mao MJ; Ye YF; Yu YH; Liang H; Yang J; Ke LR; Qiu WZ; Huang XJ; Li WZ; Guo X; Xiang YQ; Xia WX
Cancer Commun (Lond); 2018 May; 38(1):21. PubMed ID: 29764487
[TBL] [Abstract][Full Text] [Related]
14. Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fractionation in patients with locoregionally advanced nasopharyngeal carcinoma.
Lee AW; Ngan RK; Tung SY; Cheng A; Kwong DL; Lu TX; Chan AT; Chan LL; Yiu H; Ng WT; Wong F; Yuen KT; Yau S; Cheung FY; Chan OS; Choi H; Chappell R
Cancer; 2015 Apr; 121(8):1328-38. PubMed ID: 25529384
[TBL] [Abstract][Full Text] [Related]
15. CD3+T-lymphocyte infiltration is an independent prognostic factor for advanced nasopharyngeal carcinoma.
Al-Rajhi N; Soudy H; Ahmed SA; Elhassan T; Mohammed SF; Khoja HA; Ghebeh H
BMC Cancer; 2020 Mar; 20(1):240. PubMed ID: 32199452
[TBL] [Abstract][Full Text] [Related]
16. Association between single nucleotide polymorphisms in the p53 pathway and response to radiotherapy in patients with nasopharyngeal carcinoma.
Xie X; Jin H; Hu J; Zeng Y; Zhou J; Ouyang S; Yang W; Hu B; Wang H
Oncol Rep; 2014 Jan; 31(1):223-31. PubMed ID: 24173110
[TBL] [Abstract][Full Text] [Related]
17. Tumor Volume Predicts Survival Rate of Advanced Nasopharyngeal Carcinoma Treated with Concurrent Chemoradiotherapy.
Qin L; Wu F; Lu H; Wei B; Li G; Wang R
Otolaryngol Head Neck Surg; 2016 Oct; 155(4):598-605. PubMed ID: 27071443
[TBL] [Abstract][Full Text] [Related]
18. A new prognostic histopathologic classification of nasopharyngeal carcinoma.
Wang HY; Chang YL; To KF; Hwang JS; Mai HQ; Feng YF; Chang ET; Wang CP; Kam MK; Cheah SL; Lee M; Gao L; Zhang HZ; He JH; Jiang H; Ma PQ; Zhu XD; Zeng L; Chen CY; Chen G; Huang MY; Fu S; Shao Q; Han AJ; Li HG; Shao CK; Huang PY; Qian CN; Lu TX; Li JT; Ye W; Ernberg I; Ng HK; Wee JT; Zeng YX; Adami HO; Chan AT; Shao JY
Chin J Cancer; 2016 May; 35():41. PubMed ID: 27146632
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study.
Qiu WZ; Huang PY; Shi JL; Xia HQ; Zhao C; Cao KJ
Chin J Cancer; 2016 Jan; 35():2. PubMed ID: 26739148
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Value of Plasma Epstein-Barr Virus DNA for Local and Regionally Advanced Nasopharyngeal Carcinoma Treated With Cisplatin-Based Concurrent Chemoradiotherapy in Intensity-Modulated Radiotherapy Era.
Chen WH; Tang LQ; Guo SS; Chen QY; Zhang L; Liu LT; Qian CN; Guo X; Xie D; Zeng MS; Mai HQ
Medicine (Baltimore); 2016 Feb; 95(5):e2642. PubMed ID: 26844482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
